



11-18-05

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/932677-Conf. #5945
	Filing Date	August 16, 2001
	First Named Inventor	Donald F. WEAVER
	Art Unit	1624
	Examiner Name	D. R. Rao
Total Number of Pages in This Submission	Attorney Docket Number	NCI-006DV1

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Return Receipt Postcard; PTO form SB/08;
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Certificate of Express Mailing; Copies of Twenty-One (21) References
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Jacob G. Weintraub, M.S., J.D.		
Date	November 16, 2005	Reg. No.	56,469

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill no. EV553868851US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 16, 2005

Signature: (Jacob G. Weintraub, M.S., J.D.)



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL For FY 2005		Complete if Known	
		Application Number	09/932677-Conf. #5945
		Filing Date	August 16, 2001
		First Named Inventor	Donald F. WEAVER
		Examiner Name	D. R. Rao
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1624	
TOTAL AMOUNT OF PAYMENT	(\$) 180.00	Attorney Docket No.	NCI-006DV1

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 12-0080 Deposit Account Name: Lahive & Cockfield, LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims - = **Extra Claims** x **Fee (\$)** = **Fee Paid (\$)**

Indep. Claims - = **Extra Claims** x **Fee (\$)** = **Fee Paid (\$)**

Multiple Dependent Claims

Fee (\$) **Fee Paid (\$)**

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/50	(round up to a whole number) x	=	

4. OTHER FEE(S)


	Fees Paid (\$)
Non-English Specification, \$130 fee (no small entity discount)	
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement	180.00


SUBMITTED BY			
Signature	Registration No. (Attorney/Agent)	Telephone	
Name (Print/Type)		Date	
Jacob G. Weintraub, M.S., J.D.	56,469	(617) 227-7400	November 16, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill no. EV553868851US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 16, 2005 Signature: _____ (Jacob G. Weintraub, M.S., J.D.)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill no. EV553868851US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 16, 2005 Signature: 
(Jacob G. Weintraub, M.S., J.D.)



Docket No.: NCI-006DV1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Donald F. Weaver *et al.*

Application No.: 09/932677

Confirmation No.: 5945

Filed: August 16, 2001

Art Unit: 1624

For: ANTI-EPILEPTOGENIC AGENTS

Examiner: D. R. Rao

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application in accordance with 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. NCI-006DV1. A duplicate copy of this paper is enclosed.

Dated: November 16, 2005

GAD/EAH/JGW/SMW/mch

Respectfully submitted,

By 

Jacob G. Weintraub, M.S., J.D.

Registration No.: 56,469

LAHIVE & COCKFIELD, LLP

28 State Street


Boston, Massachusetts 02109

(617) 227-7400


(617) 742-4214 (Fax)

Agent For Applicant under 37 CFR § 1.34

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill no. EV553868851US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 16, 2005 Signature: 

(Jacob G. Weintraub, M.S., J.D.)



Docket No.: NCI-006DV1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Donald F. Weaver *et al.*

Application No.: 09/932677

Confirmation No.: 5945

Filed: August 16, 2001

Art Unit: 1624

For: ANTI-EPILEPTOGENIC AGENTS

Examiner: D. R. Rao

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application in accordance with 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. NCI-006DV1. A duplicate copy of this paper is enclosed.

Dated: November 16, 2005

GAD/EAH/JGW/SMW/mch

Respectfully submitted,

By 

Jacob G. Weintraub, M.S., J.D.

Registration No.: 56,469

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Agent For Applicant under 37 CFR § 1.34



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/932677-Conf. #5945
				Filing Date	August 16, 2001
				First Named Inventor	Donald F. WEAVER
				Art Unit	1624
				Examiner Name	D. R. Rao
Sheet	1	of	2	Attorney Docket Number	NCI-006DV1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-5,252,576	10-12-1993	Sakata et al.	
	A2*	US-6,306,909	10-23-2001	Weaver et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	JP-61236724	10-22-1986	Kyowa Hakko Kogyo Co. Ltd.		Abstr.
	B2	EP-0343050-B1	12-02-1992	Synthelabo		Abstr.
	B3	DE-4300912-A1	07-21-1994	Merck Patent GmbH		Abstr.
	B4	WO-95/19346-A1	07-20-1995	Sandoz Ltd.		
	B5	EP-0718280-A2	06-26-1996	Isagro Ricerca		
	B6	WO-98/27972-A2	07-02-1998	Texas A&M University		
	B7	GB-2327672	02-03-1999	Merck & Co. Inc.		
	B8	WO-9951572-A1	10-14-1999	Sankyo Company Limited		Abstr.
	B9	WO-99/52493-A3	10-21-1999	Texas Biotechnology Corporation		
	B10	WO-00/06570-A1	02-10-2000	Ortho-McNeil Pharmaceutical, Inc.		
	B11	WO-00/11952-A1	03-09-2000	Pro-Neuron, Inc.		
	B12	WO-00/50043-A1	08-31-2000	The Regents of the University of California		
	B13	WO-00/56715-A1	09-28-2000	Ortho-McNeil Pharmaceutical, Inc.		
	B14	WO-01/51490-A1	07-19-2001	The Government of the United States of America		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Baker, B.R., et al., "Irreversible Enzyme Inhibitors. LXXX.1.2 Inhibitors of Thymidine Phosphorylase. VI.2 Hydrophobic Bonding with 6 Substituents on the Acidic 5-Nitro- and 5-Bromouracils," <i>J. Med. Chem.</i> , Vol. 10(3):316-320 (1967)	
	C2	Huxtable, R., et al., "The prolonged anticonvulsant action of taurine on genetically determined seizure-susceptibility," <i>CAPLUS</i> , Accession No. 1978:470974, 1 page (1978)	
	C3	Connolly, Gerald P., et al., "Uridine and its nucleotides: biological actions, therapeutic potentials," <i>TIPS</i> , Vol. 20:218-225 (1999)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/932677-Conf. #5945
				Filing Date	August 16, 2001
				First Named Inventor	Donald F. WEAVER
				Art Unit	1624
				Examiner Name	D. R. Rao
Sheet	2	of	2	Attorney Docket Number	NCI-006DV1

	C4	Matsui, Masaki, et al., "Ozonolysis of Substituted Uracils," <i>J. Org. Chem.</i> , Vol. 55:1396-1399 (1990)	
	C5	Skulnick, Harvey I., et al., "Pyrimidinones. 3. N-Substituted 6-Phenylpyrimidinones and Pyrimidinediones with Diuretic/Hypotensive and Antiinflammatory Activity," <i>J. Med. Chem.</i> , Vol. 29:1499-1504 (1986)	
	C6	Tateoka, Yuji, et al., "Potentiating Effects of N ¹ , N ³ -Diallyluracil, N ¹ , N ³ -Diallylthymine and N ¹ , N ³ -Diallyl-6-methyluracil on Pentobarbital-Induced Sleep and Diazepam-Induced Motor Incoordination," <i>Chem. Pharm. Bull.</i> , Vol. 35(12):4928-4934 (1987)	
	C7	Temkin, Nancy R., et al., "Antiepileptogenic Agents, How Close Are We?" <i>Drugs</i> , Vol. 61(8):1045-1055 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 09/932677


Attorney Docket No.: NCI-006DV1

Certificate of Express Mailing under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail, Airbill no. EV553868851US, in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 16, 2005
Date



Signature

Jacob G. Weintraub, M.S., J.D.

Typed or printed name of person signing Certificate

56,469
Registration Number, if applicable

(617) 227-7400
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard
Transmittal Form (1 page)
Fee Transmittal (1 page, in duplicate)
Supplemental Information Disclosure Statement (2 pages, in duplicate)
PTO form SB/08 (Listing 23 References) (2 pages)
Copies of Twenty-one (21) References
This Certificate of Express Mailing (1 page)
Charge \$180.00 to deposit account 12-0080